Lindborg will discuss the expansion of Brainstorm's technology portfolio, which includes autologous and allogeneic product candidates covering multiple neurological diseases. The company completed a phase III trial of NurOwn in amyotrophic lateral sclerosis patients, according to the company.

The presentation will be available as an on-demand webinar that will be available beginning October 12. At the conclusion of the meeting, a copy of the presentation will also be available in the Investors and Media section of the BrainStorm website under Events and Presentations.